查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1386268

标籤先天性黑蒙市场报告：2030 年趋势、预测与竞争分析

Leber Congenital Amaurosis Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

莱伯先天性黑蒙趋势与预测

到 2030 年，全球标籤先天性黑蒙市场预计将达到 12.6 亿美元，2024 年至 2030 年年复合成长率为 4.2%。该市场的主要驱动因素是rpe65基因介导的视网膜疾病的盛行率不断增加、世界各国政府增加LCA研究支出以及製药公司增加投资。全球标籤先天性黑蒙（LPA）市场的未来前景看好，医院、专科诊所、门诊手术中心和家庭医疗保健市场都有商机。

标籤先天性黑蒙市场洞察

Lucintel 预测，由于 LCA 有效治疗的需求未得到满足，该治疗将在预测期内出现强劲增长。

医院将继续成为该市场中最大的部分，因为它们提供诊断和治疗 LCA 所需的设备和专业知识。

由于其发达的医疗基础设施，预计北美在预测期内仍将是最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和业务风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球标籤先天性黑蒙市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球标籤先天性黑蒙市场趋势（2018-2023）与预测（2024-2030）
  • 按类型分類的全球标籤先天性黑蒙市场
    • 治疗
    • 诊断
  • 按疾病类型分類的全球标籤先天性黑蒙市场
    • 婴儿型
    • 少年型
    • 其他的
  • 按最终用途分類的全球标籤先天性黑蒙市场
    • 医院
    • 专科诊所
    • 门诊手术中心
    • 家庭保健
    • 其他的
  • 按配销通路的全球标籤先天性黑蒙市场
    • 直接竞标
    • 零售

第4章2018-2030年分地区市场趋势及预测分析

  • 按地区分類的全球标籤先天性黑蒙市场
  • 北美标籤先天性黑蒙市场
  • 欧洲标籤先天性黑蒙市场
  • 亚太标籤先天性黑蒙市场
  • 其他地区标籤先天性黑蒙市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球标籤先天性黑蒙市场成长机会（按类型）
    • 全球标籤先天性黑蒙市场成长机会（依疾病类型）
    • 全球标籤先天性黑蒙市场成长机会（依最终用途）
    • 全球标籤先天性黑蒙市场成长机会（按配销通路）
    • 全球标籤先天性黑蒙市场成长机会（按地区）
  • 全球标籤先天性黑蒙市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球标籤先天性黑蒙市场的容量
    • 全球标籤先天性黑蒙市场的合併、收购与合资企业
    • 认证和许可

第7章主要企业概况

  • Invitae Corporation
  • Spark Therapeutics
  • LKC Technologies
  • CENTOGENE
  • Optos
  • Metrovision
  • Blue Print Genetics Oy
  • CD Genomics
  • ProQR Therapeutics
  • OCUGEN
简介目录

Leber Congenital Amaurosis Trends and Forecast

The future of the global leber congenital amaurosis (LPA) market looks promising with opportunities in the hospital, specialty clinic, ambulatory surgical center, and home healthcare markets. The global leber congenital amaurosis market is expected to reach an estimated $1.26 billion by 2030 with a CAGR of 4.2% from 2024 to 2030. The major drivers for this market are growing incidence of rpe65 gene-mediated in retinal diseases, governments around the world are increasing funding for research into LCA, and rising investment from pharmaceutical companies.

A more than 150-page report is developed to help in your business decisions.

Leber Congenital Amaurosis by Segment

The study includes a forecast for the global leber congenital amaurosis by type, disease type, end use, distribution channel, and region.

Leber Congenital Amaurosis Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Therapy
  • Diagnosis

Leber Congenital Amaurosis Market by Disease Type [Shipment Analysis by Value from 2018 to 2030]:

  • Infantile Type
  • Juvenile Type
  • Others

Leber Congenital Amaurosis Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Others

Leber Congenital Amaurosis Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Direct Tender
  • Retail Sales

Leber Congenital Amaurosis Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Leber Congenital Amaurosis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies leber congenital amaurosis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the leber congenital amaurosis companies profiled in this report include-

  • Invitae Corporation
  • Spark Therapeutics
  • LKC Technologies
  • CENTOGENE
  • Optos
  • Metrovision
  • Blue Print Genetics Oy
  • CD Genomics
  • ProQR Therapeutics
  • OCUGEN

Leber Congenital Amaurosis Market Insights

Lucintel forecasts that therapy is expected to witness higher growth over the forecast period due to growing unmet need for effective treatments for LCA.

Within this market, hospital will remain the largest segment as it provides necessary equipment and expertise to diagnose and treat LCA.

North America will remain the largest region over the forecast period due to a well-developed healthcare infrastructure.

Features of the Global Leber Congenital Amaurosis Market

Market Size Estimates: Leber congenital amaurosis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Leber congenital amaurosis market size by various segments, such as by type, disease type, end use, distribution channel, and region in terms of ($B).

Regional Analysis: Leber congenital amaurosis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, disease types, end uses, distribution channels, and regions for the leber congenital amaurosis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the leber congenital amaurosis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the leber congenital amaurosis market size?

Answer: The global leber congenital amaurosis market is expected to reach an estimated $1.26 billion by 2030.

Q.2 What is the growth forecast for leber congenital amaurosis market?

Answer: The global leber congenital amaurosis market is expected to grow with a CAGR of 4.2% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the leber congenital amaurosis market?

Answer: The major drivers for this market are growing incidence of rpe65 gene-mediated in retinal diseases, governments around the world are increasing funding for research into LCA, and rising investment from pharmaceutical companies.

Q4. What are the major segments for leber congenital amaurosis market?

Answer: The future of the leber congenital amaurosis market (LCA) looks promising with opportunities in the hospital, specialty clinic, ambulatory surgical center, and home healthcare markets.

Q5. Who are the key leber congenital amaurosis market companies?

Answer: Some of the key leber congenital amaurosis companies are as follows:

  • Invitae Corporation
  • Spark Therapeutics
  • LKC Technologies
  • CENTOGENE
  • Optos
  • Metrovision
  • Blue Print Genetics Oy
  • CD Genomics
  • ProQR Therapeutics
  • OCUGEN

Q6. Which leber congenital amaurosis market segment will be the largest in future?

Answer: Lucintel forecasts that therapy is expected to witness higher growth over the forecast period due to growing unmet need for effective treatments for LCA.

Q7. In leber congenital amaurosis market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to a well-developed healthcare infrastructure.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the leber congenital amaurosis market by type (therapy and diagnosis), disease type (infantile type, juvenile type , and others), end use (hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others), distribution channel (direct tender and retail sales), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Leber Congenital Amaurosis Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Leber Congenital Amaurosis Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Leber Congenital Amaurosis Market by Type
    • 3.3.1: Therapy
    • 3.3.2: Diagnosis
  • 3.4: Global Leber Congenital Amaurosis Market by Disease Type
    • 3.4.1: Infantile Type
    • 3.4.2: Juvenile Type
    • 3.4.3: Others
  • 3.5: Global Leber Congenital Amaurosis Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Specialty Clinics
    • 3.5.3: Ambulatory Surgical Centers
    • 3.5.4: Home Healthcare
    • 3.5.5: Others
  • 3.6: Global Leber Congenital Amaurosis Market by Distribution Channel
    • 3.6.1: Direct Tender
    • 3.6.2: Retail Sales

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Leber Congenital Amaurosis Market by Region
  • 4.2: North American Leber Congenital Amaurosis Market
    • 4.2.2: North American Leber Congenital Amaurosis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others
  • 4.3: European Leber Congenital Amaurosis Market
    • 4.3.1: European Leber Congenital Amaurosis Market by Type: Therapy and Diagnosis
    • 4.3.2: European Leber Congenital Amaurosis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others
  • 4.4: APAC Leber Congenital Amaurosis Market
    • 4.4.1: APAC Leber Congenital Amaurosis Market by Type: Therapy and Diagnosis
    • 4.4.2: APAC Leber Congenital Amaurosis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others
  • 4.5: ROW Leber Congenital Amaurosis Market
    • 4.5.1: ROW Leber Congenital Amaurosis Market by Type: Therapy and Diagnosis
    • 4.5.2: ROW Leber Congenital Amaurosis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Leber Congenital Amaurosis Market by Type
    • 6.1.2: Growth Opportunities for the Global Leber Congenital Amaurosis Market by Disease Type
    • 6.1.3: Growth Opportunities for the Global Leber Congenital Amaurosis Market by End Use
    • 6.1.4: Growth Opportunities for the Global Leber Congenital Amaurosis Market by Distribution Channel
    • 6.1.5: Growth Opportunities for the Global Leber Congenital Amaurosis Market by Region
  • 6.2: Emerging Trends in the Global Leber Congenital Amaurosis Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Leber Congenital Amaurosis Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Leber Congenital Amaurosis Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Invitae Corporation
  • 7.2: Spark Therapeutics
  • 7.3: LKC Technologies
  • 7.4: CENTOGENE
  • 7.5: Optos
  • 7.6: Metrovision
  • 7.7: Blue Print Genetics Oy
  • 7.8: CD Genomics
  • 7.9: ProQR Therapeutics
  • 7.10: OCUGEN